ArticleScientific reports2024
Artificial intelligence-assisted magnetic resonance imaging technology in the differential diagnosis and prognosis prediction of endometrial cancer.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Review
- Integrating artificial intelligence and multi-omics data for precision oncology in endometrial cancer: a narrative review.Functional & integrative genomics · 2026Review
- AI-engineered multifunctional nanoplatforms: synergistically bridging precision diagnosis and intelligent therapy in next-generation oncology.Journal of nanobiotechnology · 2025Review
- Hybrid ResNet-ViT Framework for Endometrial Lesion Analysis: A Comparative Study of MRI and CT in Endometrial Cancer Classification.International journal of women's health · 2025Article
- Artificial intelligence-based magnetic resonance imaging for preoperative staging of patients with endometrial cancer: a systematic review and meta-analysis.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It aimed to analyze the value of deep learning algorithm combined with magnetic resonance imaging (MRI) in the risk diagnosis and prognosis of endometrial cancer (EC). Based on the deep learning convolutional neural network (CNN) architecture residual network with 101 layers (ResNet-101), spatial attention and channel attention modules were introduced to optimize the model. A retrospective collection of MRI image data from 210 EC patients was used for model segmentation and reconstruction, with 140 cases as the test set and 70 cases as the validation set. The performance was compared with traditional ResNet-101 model, ResNet-101 model based on spatial attention mechanism (SA-ResNet-101), and ResNet-101 model based on channel attention mechanism (CA-ResNet-101), using accuracy (AC), precision (PR), recall (RE), and F1 score as evaluation metrics. Among the 70 cases in the validation set, there were 45 cases of low-risk EC and 25 cases of high-risk EC. Using ROC curve analysis, it was found that the area under the curve (AUC) for the diagnosis of high-risk EC of the proposed model in this article (0.918) was visibly larger as against traditional ResNet-101 (0.613), SA-ResNet-101 (0.760), and CA-ResNet-101 models (0.758). The AC, PR, RE, and F1 values of the proposed model for the diagnosis of EC risk were visibly higher (P < 0.05). In the validation set, postoperative recurrence occurred in 13 cases and did not occur in 57 cases. Using ROC curve analysis, it was found that the AUC for postoperative recurrence prediction of the patients by the proposed model (0.926) was visibly larger as against traditional ResNet-101 (0.620), SA-ResNet-101 (0.729), and CA-ResNet-101 models (0.767). The AC, PR, RE, and F1 values of the proposed model for postoperative recurrence prediction were visibly higher (P < 0.05). The proposed model in this article, assisted by MRI, presented superior performance in diagnosing high-risk EC patients, with higher sensitivity (Sen) and specificity (Spe), and also demonstrated excellent predictive AC in postoperative recurrence prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.